Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of “Moderate Buy” by Analysts

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have received a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $175.33.

A number of equities research analysts recently weighed in on JAZZ shares. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. TD Cowen cut their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Finally, Royal Bank of Canada raised their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, October 23rd.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now owns 427,025 shares in the company, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,753 shares of company stock valued at $816,289 over the last 90 days. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. LSV Asset Management boosted its position in shares of Jazz Pharmaceuticals by 4.2% during the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock valued at $264,750,000 after buying an additional 99,705 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Baupost Group LLC MA grew its stake in shares of Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after acquiring an additional 440,552 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Jazz Pharmaceuticals by 48.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock valued at $130,447,000 after purchasing an additional 398,549 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after purchasing an additional 48,708 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Down 0.4 %

JAZZ opened at $122.59 on Monday. The company’s 50 day moving average is $116.18 and its 200-day moving average is $111.63. The company has a market cap of $7.41 billion, a P/E ratio of 17.27, a PEG ratio of 1.04 and a beta of 0.57. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.